Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
18.51
+0.02 (0.11%)
Sep 2, 2026, 4:00 PM EDT - Market closed
Relay Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 10.35 | 15.36 | 10.01 | 25.55 | 1.38 | 3.03 | |
Revenue Growth | 23.88% | 53.44% | -60.83% | 1749.82% | -54.41% | -96.34% |
Cost of Revenue | 268.85 | 257.21 | 315.44 | 326.39 | 243.01 | 169.39 |
Gross Profit | -258.5 | -241.85 | -305.43 | -300.84 | -241.62 | -166.36 |
Selling, General & Admin | 51.94 | 58.59 | 80.24 | 78.58 | 69.33 | 59.75 |
Operating Expenses | 51.94 | 58.59 | 80.24 | 78.58 | 69.33 | 59.75 |
Operating Income | -310.44 | -300.44 | -385.67 | -379.42 | -310.95 | -226.11 |
Interest & Investment Income | 24.58 | 27.04 | 34.75 | 31.05 | 8.79 | 0.83 |
Other Non Operating Income (Expenses) | -0.19 | -0.78 | 0.01 | -0.02 | -0.02 | -0 |
EBT Excluding Unusual Items | -286.04 | -274.18 | -350.91 | -348.4 | -302.19 | -225.28 |
Merger & Restructuring Charges | - | - | - | - | - | -0.9 |
Gain (Loss) on Sale of Investments | - | - | - | - | - | -11.86 |
Asset Writedown | - | -2.3 | - | - | - | - |
Other Unusual Items | - | - | 13.21 | 6.42 | 11.68 | -2.84 |
Pretax Income | -286.04 | -276.48 | -337.71 | -341.97 | -290.51 | -363.87 |
Net Income | -286.04 | -276.48 | -337.71 | -341.97 | -290.51 | -363.87 |
Net Income to Common | -286.04 | -276.48 | -337.71 | -341.97 | -290.51 | -363.87 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 182 | 172 | 143 | 123 | 112 | 95 |
Shares Outstanding (Diluted) | 182 | 172 | 143 | 123 | 112 | 95 |
Shares Change | 12.39% | 20.10% | 16.55% | 9.21% | 17.97% | 123.22% |
EPS (Basic) | -1.57 | -1.61 | -2.36 | -2.79 | -2.59 | -3.82 |
EPS (Diluted) | -1.57 | -1.61 | -2.36 | -2.79 | -2.59 | -3.82 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -212.21 | -235.87 | -251.13 | -304.44 | -238.55 | -77.88 |
Free Cash Flow Per Share | -1.17 | -1.38 | -1.76 | -2.48 | -2.13 | -0.82 |
Operating Margin | -2999.37% | -1956.61% | -3854.04% | -1485.25% | -22516.44% | -7464.74% |
Profit Margin | -2763.64% | -1800.58% | -3374.72% | -1338.66% | -21036.13% | -12012.94% |
Free Cash Flow Margin | -2050.29% | -1536.08% | -2509.49% | -1191.74% | -17273.86% | -2571.05% |
EBITDA | -308.22 | -296.88 | -380.21 | -374.15 | -306.82 | -222.18 |
D&A For EBITDA | 2.21 | 3.56 | 5.46 | 5.27 | 4.13 | 3.93 |
EBIT | -310.44 | -300.44 | -385.67 | -379.42 | -310.95 | -226.11 |
Revenue as Reported | 10.35 | 15.36 | 10.01 | 25.55 | 1.38 | 3.03 |